Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: RPGN
← New Search

RPGN

RPGN (rapidly progressive glomerulonephritis): full form, immunofluorescence types, urgent labs, biopsy, and management outline for students and clinicians.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is intended for educational purposes and as a general reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be based on the individual patient's condition, the clinician's judgment, and the most current evidence-based guidelines. Consult with specialists as needed.

Overview

  • Definition: Rapidly Progressive Glomerulonephritis (RPGN) is a clinical syndrome characterized by a rapid and progressive decline in glomerular filtration rate (GFR) over a short period (days, weeks, or up to 3 months), often leading to acute kidney injury (AKI). Histopathologically, it is almost universally associated with extensive glomerular crescent formation (involving ≥50% of glomeruli) on kidney biopsy, which signifies severe glomerular injury.
  • Epidemiology: RPGN is relatively rare, but it is a leading cause of AKI requiring dialysis. Its incidence varies depending on the underlying cause:
    • ANCA-associated vasculitis (AAV) is the most common cause globally, with an incidence of approximately 10-20 cases per million population per year.
    • Anti-glomerular basement membrane (GBM) disease accounts for 10-15% of RPGN cases, with an incidence of about 1 case per million per year.
    • Immune complex-mediated RPGN (e.g., lupus nephritis, post-infectious glomerulonephritis, IgA vasculitis) constitutes 20-30% of cases.
    • RPGN can occur at any age but is more common in older adults, except for post-infectious causes which are more prevalent in children.
  • Classification: RPGN is classified based on immunopathologic findings on kidney biopsy and serologic markers, which guide diagnosis and treatment:
    1. Type I (Anti-GBM Disease): Characterized by linear deposition of IgG antibodies along the glomerular basement membrane (GBM) on immunofluorescence (IF) microscopy. Often associated with circulating anti-GBM antibodies. Can occur in isolation or with pulmonary hemorrhage (Goodpasture's syndrome).
    2. Type II (Immune Complex RPGN): Characterized by granular deposition of immune complexes (IgG, IgA, IgM, C3, C1q) on IF. This type encompasses various conditions:
      • Systemic lupus erythematosus (SLE) nephritis (most common)
      • Post-infectious glomerulonephritis (e.g., post-streptococcal)
      • IgA vasculitis (Henoch-Schönlein Purpura)
      • Cryoglobulinemic vasculitis
      • Membranoproliferative glomerulonephritis (MPGN)
      • Other conditions (e.g., fibrillary glomerulonephritis)
    3. Type III (Pauci-immune RPGN): Characterized by scant or no immune complex deposition on IF, indicating an absence of significant antibody or complement deposition. Strong association with circulating anti-neutrophil cytoplasmic antibodies (ANCA), specifically:
      • Granulomatosis with Polyangiitis (GPA), previously Wegener's granulomatosis (often PR3-ANCA positive, c-ANCA pattern)
      • Microscopic Polyangiitis (MPA) (often MPO-ANCA positive, p-ANCA pattern)
      • Eosinophilic Granulomatosis with Polyangiitis (EGPA), previously Churg-Strauss syndrome (often MPO-ANCA positive)
      • Less commonly, drug-induced ANCA vasculitis or idiopathic pauci-immune.
    4. Type IV (Mixed RPGN): A rare subset where features of both anti-GBM disease and ANCA-associated vasculitis are present, often with both anti-GBM antibodies and ANCA.
    5. Type V (Double-Positive RPGN): Some classifications refer to cases with dual positive serology (e.g., ANCA + Anti-GBM). This might overlap with Type IV or be considered a distinct rare entity.

Pathophysiology

  • Mechanism: The unifying pathological feature of RPGN is the rapid proliferation of parietal epithelial cells (that line Bowman's capsule) and infiltration of monocytes/macrophages into Bowman's space, leading to the formation of "crescents." These crescents compress the glomerular tuft, disrupting filtration and causing rapid loss of kidney function. Fibrin deposition within Bowman's space is also common, contributing to crescent formation.
    • Type I (Anti-GBM): Circulating anti-GBM antibodies bind to specific non-collagenous (NC1) domains of type IV collagen in the glomerular and alveolar basement membranes. This activates complement and recruits inflammatory cells (neutrophils, macrophages), leading to severe necrotizing glomerulonephritis and sometimes pulmonary capillaritis.
    • Type II (Immune Complex): Deposition of circulating or in situ formed immune complexes within the glomerular capillaries or mesangium triggers inflammation, complement activation, and leukocyte recruitment. The specific immune complex composition and location determine the pattern of injury. For example, in SLE, complexes deposit subendothelially, leading to severe inflammation and necrosis.
    • Type III (Pauci-immune): ANCA antibodies (PR3 or MPO) activate neutrophils, leading to their degranulation and release of reactive oxygen species and proteolytic enzymes. These enzymes damage endothelial cells, particularly within small vessels, causing necrotizing vasculitis without significant immune deposits. This directly results in glomerular capillary wall rupture and crescent formation.
  • Risk Factors:
    • Genetic Predisposition: HLA-DRB1*1501 and HLA-DR4 are associated with anti-GBM disease. Specific HLA alleles and PTPN22 polymorphisms are linked to ANCA-associated vasculitis.
    • Infections: Prior streptococcal infection (post-streptococcal GN), bacterial endocarditis, viral infections (e.g., Hepatitis B/C, HIV) can trigger immune complex GN.
    • Autoimmune Diseases: Pre-existing autoimmune conditions like SLE, rheumatoid arthritis, Sjögren's syndrome increase risk for immune complex GN or secondary vasculitis.
    • Drug Exposure: Certain medications (e.g., propylthiouracil, hydralazine, minocycline, allopurinol, D-penicillamine) can induce ANCA formation.
    • Environmental Factors: Exposure to silica (for ANCA-associated vasculitis).
    • Smoking: Potentiates lung hemorrhage in anti-GBM disease.
  • Protective Factors: There are no established primary protective factors against developing RPGN, as it is largely an autoimmune or severe inflammatory process. However, early diagnosis and prompt, aggressive immunosuppressive treatment are critical secondary protective factors to preserve kidney function and prevent end-stage renal disease (ESRD).

Clinical Presentation

Signs and Symptoms

  • Cardinal Features:
    • Rapid decline in kidney function: Manifests as rapidly rising serum creatinine and blood urea nitrogen (BUN).
    • Hematuria: Often macroscopic (dark, smoky urine) or microscopic with dysmorphic red blood cells (RBCs) and RBC casts (highly specific for glomerular bleeding).
    • Proteinuria: Variable, usually non-nephrotic range but can be nephrotic (>3.5 g/day) in some cases (e.g., lupus nephritis).
    • Oliguria or anuria: May develop rapidly as kidney function deteriorates.
    • Hypertension: Common due to fluid overload and renin-angiotensin system activation.
    • Edema: Peripheral edema, facial puffiness due to fluid retention.
    • Non-specific systemic symptoms: Fatigue, malaise, anorexia, nausea, weight loss, low-grade fever.
  • Early Signs:
    • Fatigue, generalized weakness.
    • Subtle increase in serum creatinine, often mistaken for other causes of AKI.
    • Microscopic hematuria with or without mild proteinuria on routine urinalysis.
    • Mild, unexplainable edema.
  • Advanced Signs:
    • Uremic symptoms: Severe nausea, vomiting, confusion, lethargy, asterixis, pericarditis, pleuritis, uremic pruritus.
    • Severe anasarca (generalized edema), pulmonary edema, shortness of breath.
    • Pulmonary hemorrhage: Especially common in Anti-GBM disease and ANCA-associated vasculitis (GPA, MPA) presenting as hemoptysis, dyspnea, and respiratory failure (diffuse alveolar hemorrhage). This combination is often referred to as "pulmonary-renal syndrome."
    • Other systemic manifestations depending on etiology:
      • ANCA-associated vasculitis: Sinusitis, otitis, epistaxis, nasal crusting (GPA), skin rash (purpura), arthralgia, mononeuritis multiplex, ocular inflammation.
      • SLE: Arthralgia/arthritis, malar rash, photosensitivity, serositis, neurological symptoms.
      • IgA vasculitis: Palpable purpura (especially on lower extremities), arthralgia, abdominal pain.
      • Cryoglobulinemia: Palpable purpura, arthralgia, peripheral neuropathy.
  • Atypical Presentations:
    • Isolated renal involvement without significant systemic symptoms (can occur in pauci-immune or anti-GBM disease).
    • Subacute onset mimicking chronic kidney disease.
    • Presentations dominated by extra-renal symptoms (e.g., severe pulmonary hemorrhage without obvious renal symptoms initially, or severe rash masking underlying kidney involvement).

Physical Examination

  • Inspection:
    • Edema: Periorbital, facial, sacral, peripheral (pitting edema of extremities).
    • Skin: Palpable purpura (especially on lower extremities in vasculitis), malar rash (SLE), livedo reticularis, skin ulcers.
    • Mucosa: Oral ulcers (SLE, GPA), nasal septal perforation (GPA).
    • Respiratory: Signs of respiratory distress, tachypnea, hemoptysis (if pulmonary hemorrhage).
    • General: Pallor (anemia), signs of cachexia or chronic illness.
  • Palpation:
    • Cardiovascular: Tachycardia, elevated blood pressure (hypertension), signs of fluid overload (jugular venous distension, S3 gallop, hepatojugular reflux).
    • Abdomen: Ascites, flank pain (rare).
    • Extremities: Tenderness in joints (arthralgia/arthritis), muscle weakness.
  • Special Tests:
    • Cardiopulmonary auscultation: Rales/crackles (pulmonary edema, pulmonary hemorrhage), pleural effusions (dullness to percussion, decreased breath sounds), pericardial rub (uremic pericarditis).
    • Neurological exam: Assessment for altered mental status, peripheral neuropathy, cranial nerve palsies (in severe vasculitis).
    • Fundoscopy: Retinal hemorrhages, cotton wool spots (hypertensive retinopathy, vasculitis).

Diagnostic Approach

History Taking

  • Key Questions:
    • Onset and Progression: When did symptoms begin? How rapidly have they progressed (days, weeks, months)?
    • Renal Symptoms: Changes in urine output (oliguria, anuria), urine color (dark, smoky, red), frequency, dysuria. Edema?
    • Systemic Symptoms: Fever, weight loss, fatigue, night sweats, arthralgia/arthritis, skin rashes (onset, location, character), muscle weakness.
    • Respiratory Symptoms: Cough, shortness of breath, hemoptysis (coughing up blood), chest pain.
    • ENT Symptoms: Sinus pain, congestion, nosebleeds, hearing loss.
    • Neurological Symptoms: Headache, visual disturbances, numbness, tingling, weakness, seizures, altered mental status.
    • Gastrointestinal Symptoms: Abdominal pain, nausea, vomiting, diarrhea, blood in stool.
    • Past Medical History: Recent infections (especially streptococcal, viral), autoimmune diseases (SLE, RA), chronic liver disease, malignancy, diabetes, hypertension.
    • Medication History: All current and recent medications, including over-the-counter drugs, illicit drugs, and herbal supplements (especially those associated with drug-induced ANCA).
    • Family History: Any family history of kidney disease, autoimmune conditions, or vasculitis.
    • Social History: Smoking, alcohol use, occupational exposures.
  • Red Flags:
    • Rapidly rising serum creatinine (e.g., doubling in days to weeks).
    • New-onset oliguria or anuria.
    • Hemoptysis or other signs of diffuse alveolar hemorrhage in conjunction with renal decline.
    • New vasculitic rash (palpable purpura).
    • Neurological changes (e.g., altered mental status, new focal neurological deficits).
    • Evidence of multi-organ involvement (e.g., lung, skin, joints, GI).

Laboratory Tests

  • First-Line:
    • Serum Creatinine, BUN, Electrolytes: To assess kidney function and detect uremia, hyperkalemia, metabolic acidosis. Trend creatinine to establish rate of decline.
    • Complete Blood Count (CBC): May show anemia (due to chronic disease or hemorrhage), leukocytosis (inflammation/infection), eosinophilia (EGPA).
    • Urinalysis with Microscopy: Critical. Look for:
      • Hematuria: Gross or microscopic.
      • Dysmorphic Red Blood Cells: Indicative of glomerular origin.
      • Red Blood Cell Casts: Pathognomonic for glomerulonephritis.
      • Proteinuria: Quantify with urine protein-to-creatinine ratio (UPCR) or 24-hour urine collection.
    • Erythrocyte Sedimentation Rate (ESR) and C-reactive Protein (CRP): Often markedly elevated, indicating systemic inflammation.
  • Confirmatory (and Etiology-Specific):
    • Kidney Biopsy: The gold standard for diagnosis and classification. Essential to confirm crescentic glomerulonephritis, determine the percentage of crescents (cellular vs. fibrous/sclerotic), and identify the underlying immunopathologic type (linear IgG, granular immune complexes, or pauci-immune). Provides critical prognostic information. Biopsy should be performed urgently.
    • Serological Markers:
      • Antinuclear Antibodies (ANA) with ENA panel (anti-dsDNA, anti-Sm, anti-Ro, anti-La): For systemic lupus erythematosus.
      • Anti-Neutrophil Cytoplasmic Antibodies (ANCA):
        • PR3-ANCA (c-ANCA pattern): Highly specific for Granulomatosis with Polyangiitis (GPA).
        • MPO-ANCA (p-ANCA pattern): Highly specific for Microscopic Polyangiitis (MPA) or Eosinophilic Granulomatosis with Polyangiitis (EGPA).
        • Titers often correlate with disease activity.
      • Anti-Glomerular Basement Membrane (Anti-GBM) Antibodies: Confirmatory for Anti-GBM disease. Very high titers are typical.
      • Complement Levels (C3, C4, CH50):
        • Low C3/C4 suggests immune complex-mediated disease (e.g., SLE, post-infectious GN, cryoglobulinemia, MPGN).
        • Normal C3/C4 typically seen in ANCA-associated vasculitis and anti-GBM disease.
      • Anti-Streptolysin O (ASO) titer and Anti-DNase B: If post-streptococcal GN is suspected.
      • Cryoglobulins: For cryoglobulinemic vasculitis.
      • Hepatitis B & C serologies, HIV testing: To rule out underlying infections that can cause immune complex GN.
      • Serum Protein Electrophoresis (SPEP) and Urine Protein Electrophoresis (UPEP) with immunofixation: To rule out monoclonal gammopathy (e.g., light chain deposition disease).
  • Monitoring:
    • Serial Creatinine and BUN: To monitor response to treatment and kidney function.
    • Urinalysis: To track hematuria and proteinuria.
    • Blood Pressure: Daily monitoring.
    • CBC with differential: To monitor for bone marrow suppression (e.g., from cyclophosphamide) or infection.
    • Liver function tests, electrolytes: To monitor for medication side effects.
    • Specific serological markers (e.g., ANCA titers, anti-GBM titers): In some cases, to monitor disease activity, though clinical response and creatinine are often primary.

Imaging

  • Recommended:
    • Renal Ultrasound with Doppler: To assess kidney size, cortical thickness, and echogenicity. Rules out obstructive uropathy and can provide an estimate of chronicity (small, echogenic kidneys suggest chronic damage, normal-sized kidneys suggest acute process). Doppler helps assess renal artery flow.
  • Advanced (as indicated by symptoms):
    • Chest X-ray: To screen for pulmonary edema or diffuse alveolar hemorrhage (patchy or diffuse infiltrates).
    • High-Resolution Computed Tomography (HRCT) of the Chest: If pulmonary hemorrhage or interstitial lung disease is suspected. More sensitive for subtle infiltrates.
    • CT Sinuses/Orbits: If ENT or ocular symptoms suggest GPA.

Management

RPGN is a medical emergency requiring urgent diagnosis and aggressive treatment to preserve kidney function and prevent end-stage renal disease (ESRD) and life-threatening systemic complications.

Acute Management

  • Immediate:
    • Hospital Admission: Prompt admission to a specialized unit (e.g., nephrology, intensive care) for close monitoring and rapid intervention.
    • Establish IV access: For fluid administration and medications.
    • Assess ABCs: Airway, Breathing, Circulation, especially if pulmonary hemorrhage or severe volume overload is present.
    • Urgent Diagnostic Work-up: Rapid collection of labs (creatinine, urinalysis, serologies) and immediate planning for kidney biopsy.
  • Stabilization:
    • High-Dose Glucocorticoids: Initiate immediately even before biopsy results if RPGN is highly suspected.
      • Pulse Methylprednisolone: 500-1000 mg IV daily for 3-5 days. This rapidly suppresses inflammation and is a cornerstone of therapy for all types of RPGN.
      • Rationale: Potent anti-inflammatory and immunosuppressive effects to halt the rapid progression of glomerular damage.
    • Specific Immunosuppression (Etiology-Dependent):
      • Cyclophosphamide: For ANCA-associated vasculitis and severe immune complex RPGN (e.g., severe lupus nephritis).
        • Oral: 1.5-2 mg/kg/day (max 200 mg/day).
        • IV pulse: 0.5-0.75 g/m² body surface area (or 10-15 mg/kg) every 2-4 weeks (dose adjusted for renal function).
        • Rationale: Potent cytotoxic agent that depletes lymphocytes and inhibits B-cell activity, crucial for induction of remission.
      • Rituximab: For ANCA-associated vasculitis, increasingly used as an alternative or in combination with cyclophosphamide.
        • IV: 375 mg/m² weekly for 4 weeks (similar to lymphoma regimen) OR 1000 mg IV on days 1 and 15 (similar to rheumatoid arthritis regimen).
        • Rationale: Chimeric monoclonal antibody targeting CD20 on B-lymphocytes, leading to B-cell depletion and reduction in antibody production.
      • Plasma Exchange (Plasmapheresis):
        • Indications: Strongly recommended for Anti-GBM disease (especially with active bleeding or severe renal dysfunction) and severe ANCA-associated vasculitis (if serum creatinine >5.7 mg/dL or presence of pulmonary hemorrhage).
        • Procedure: Daily exchanges of 1.0-1.5 plasma volumes (typically 3-7 sessions). Removes pathogenic antibodies (anti-GBM, ANCA) and inflammatory mediators.
        • Rationale: Rapidly removes circulating autoantibodies and inflammatory mediators, buying time for immunosuppressive drugs to take effect.
    • Dialysis: If severe AKI leading to uremic emergencies (e.g., intractable hyperkalemia, severe metabolic acidosis, uremic encephalopathy, pericarditis, intractable fluid overload).
  • Emergency:
    • Management of Pulmonary Hemorrhage: Airway protection, supplemental oxygen, mechanical ventilation if severe, correction of coagulopathy. Plasma exchange is crucial for Goodpasture's and severe ANCA.
    • Management of Severe Hypertension: IV antihypertensives (e.g., labetalol, nicardipine, clevidipine) to prevent hypertensive emergency and target blood pressure.
    • Management of Hyperkalemia/Metabolic Acidosis: IV calcium gluconate, insulin/dextrose, sodium bicarbonate, potassium binders, or urgent dialysis.

Chronic Management (Maintenance Therapy)

Once remission is induced (usually after 3-6 months of induction therapy), patients are transitioned to less intensive maintenance therapy. - Pharmacological: * Corticosteroid Taper: Oral prednisone/prednisolone initiated at 1 mg/kg/day (max 60-80 mg/day) following pulse therapy, then slowly tapered over 6-12 months, or longer, depending on disease activity and tolerance. * Maintenance Immunosuppressants: * Azathioprine: 1.5-2 mg/kg/day orally. Commonly used for ANCA-associated vasculitis and lupus nephritis. Less myelosuppressive than cyclophosphamide. * Mycophenolate Mofetil (MMF): 1-2 g orally twice daily. Preferred in lupus nephritis, also an alternative to azathioprine in ANCA vasculitis, especially if intolerant or for relapse prevention. * Rituximab: Can be used as maintenance therapy for ANCA-associated vasculitis (e.g., 500 mg IV every 6 months for 18-24 months). * Calcineurin Inhibitors (e.g., Tacrolimus, Cyclosporine): Used in specific types of lupus nephritis (e.g., pure membranous or resistant forms) or in some resistant cases of ANCA vasculitis, but nephrotoxicity is a concern. * Blood Pressure Control: ACE inhibitors or ARBs are often preferred as they also reduce proteinuria. Target BP <130/80 mmHg. * Dyslipidemia Management: Statins. * Bone Protection: Calcium, vitamin D, and bisphosphonates due to prolonged corticosteroid use. * Pneumocystis jirovecii Pneumonia (PJP) Prophylaxis: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended while on high-dose cyclophosphamide or corticosteroids. - Non-pharmacological: * Dietary Modifications: Sodium restriction (for fluid overload/hypertension), potassium and phosphate restriction (if hyperkalemia/hyperphosphatemia develop). Protein restriction in advanced CKD. * Fluid Management: Restrict fluid intake if fluid overload or severe hyponatremia. * Smoking Cessation: Crucial for lung health, especially in pulmonary-renal syndromes. * Vaccinations: Ensure up-to-date vaccinations (e.g., influenza, pneumococcal) after disease quiescence and considering immunosuppression level. Avoid live vaccines during periods of intense immunosuppression. - Monitoring: * Regular follow-up: With a nephrologist and relevant specialists (e.g., rheumatologist, pulmonologist). * Kidney function: Serum creatinine, BUN, eGFR, urinalysis (proteinuria, hematuria) periodically (e.g., monthly initially, then every 3-6 months). * Serological markers: ANCA titers may be monitored, but clinical status and renal function are more important indicators of disease activity. Anti-GBM titers usually normalize after successful treatment. Complement levels for SLE. * Medication side effects: CBC (leukopenia, anemia), LFTs, blood pressure, glucose. * Disease Relapse: Vigilance for return of systemic symptoms or worsening renal function.

Treatment Algorithms

The specific treatment regimen depends on the underlying etiology of RPGN:

  1. Anti-GBM Disease (Type I RPGN):

    • First-Line:
      • Pulse Methylprednisolone: 500-1000 mg IV daily for 3-5 days, then oral prednisone (1 mg/kg/day, tapered).
      • Cyclophosphamide: 2 mg/kg/day orally or 0.5-0.75 g/m² IV pulses for 2-3 months.
      • Plasma Exchange: Daily 1.0-1.5 plasma volumes for 7-14 sessions or until anti-GBM antibodies are undetectable.
    • Rationale: Rapid removal of anti-GBM antibodies and suppression of antibody production and inflammation. Prognosis is best if treatment is initiated before dialysis dependence and with less severe crescentic disease.
    • Second-Line/Refractory: No established second-line for refractory anti-GBM due to rarity. Consider IVIG in rare cases. Dialysis or transplantation for ESRD.

  2. Immune Complex RPGN (Type II RPGN):

    • Lupus Nephritis (Class III/IV):
      • First-Line (Induction):
        • Pulse Methylprednisolone: 500-1000 mg IV daily for 3 days.
        • Cyclophosphamide: Monthly IV pulses (NIH regimen) OR Mycophenolate Mofetil (MMF) 2-3 g/day orally (Euro-Lupus regimen or combination with tacrolimus).
      • Maintenance: Oral prednisone taper + Azathioprine (1.5-2 mg/kg/day) or MMF (1-2 g/day).
    • Post-infectious GN:
      • First-Line: Supportive care (BP control, fluid management, dialysis if needed). Immunosuppression generally not indicated unless rapidly progressive, severe, and persistent. Antibiotics for active infection.
    • IgA Vasculitis (Henoch-Schönlein Purpura) Nephritis:
      • First-Line (for severe renal involvement): Pulse Methylprednisolone then oral prednisone, often with cyclophosphamide or MMF.
    • Refractory Cases: Consider calcineurin inhibitors (tacrolimus, cyclosporine), rituximab, or other biologics depending on the underlying specific immune complex disease.

  3. Pauci-immune RPGN (ANCA-associated vasculitis, Type III RPGN):

    • First-Line (Induction):
      • Pulse Methylprednisolone: 500-1000 mg IV daily for 3 days, then oral prednisone (1 mg/kg/day, tapered).
      • Cyclophosphamide: Oral (1.5-2 mg/kg/day) or IV pulses (0.5-0.75 g/m² every 2 weeks x3, then every 3 weeks x3).
      • OR Rituximab: 375 mg/m² IV weekly for 4 weeks OR 1000 mg IV on days 1 and 15. Rituximab is often preferred for relapsing disease or in patients where cyclophosphamide is contraindicated.
      • Plasma Exchange: Recommended if serum creatinine >5.7 mg/dL or with diffuse alveolar hemorrhage.
    • Second-Line (Maintenance):
      • Azathioprine: 1.5-2 mg/kg/day orally (for 18-24 months after cyclophosphamide induction).
      • OR Rituximab: 500 mg IV every 6 months (for 18-24 months after rituximab induction).
      • Consider low-dose oral prednisone taper for extended maintenance.
    • Refractory Cases: Consider dose escalation, switching between cyclophosphamide and rituximab, adding IVIG, or experimental therapies. Eculizumab (complement inhibitor) for atypical HUS-like presentations.

Complications

  • Common:
    • Acute Kidney Injury (AKI) leading to Chronic Kidney Disease (CKD) and ultimately End-Stage Renal Disease (ESRD) requiring dialysis or transplantation.
    • Hypertension: Due to fluid overload, renal parenchymal damage, and RAAS activation.
    • Fluid Overload: Leading to edema, pulmonary edema, pleural effusions.
    • Anemia: Due to inflammation, kidney failure, or hemorrhage.
    • Infections: Major complication due to immunosuppression, often opportunistic infections (Pneumocystis, viral, fungal).
    • Electrolyte imbalances: Hyperkalemia, hyperphosphatemia, metabolic acidosis.
  • Serious:
    • Pulmonary Hemorrhage: Life-threatening, requiring ventilatory support and aggressive immunosuppression.
    • Uremic Emergencies: Pericarditis, encephalopathy, severe hyperkalemia, severe acidosis requiring urgent dialysis.
    • Severe Sepsis/Opportunistic Infections: Due to high-dose immunosuppression.
    • Drug Toxicity: Bone marrow suppression (cyclophosphamide), hemorrhagic cystitis (cyclophosphamide), liver toxicity (azathioprine, MMF), gastrointestinal toxicity.
    • Malignancy: Long-term risk with chronic immunosuppression (e.g., skin cancer, lymphoma).
  • Long-term:
    • ESRD: A significant proportion of patients will progress to ESRD, necessitating lifelong dialysis or kidney transplantation.
    • Cardiovascular Disease: Increased risk due to CKD, hypertension, dyslipidemia, and chronic inflammation.
    • Osteoporosis and Avascular Necrosis: Due to long-term corticosteroid use.
    • Recurrence of Disease: Especially in ANCA-associated vasculitis and lupus nephritis.
    • Neurocognitive impairment: Due to chronic kidney disease and systemic disease.

Prognosis

  • Factors:
    • Type of RPGN: Anti-GBM disease generally has the poorest renal prognosis if treatment is delayed. ANCA-associated vasculitis has a better chance of renal recovery, especially if treated early.
    • Baseline Kidney Function: The most crucial prognostic factor for renal outcome. Lower serum creatinine at diagnosis and absence of dialysis dependence correlate with better renal recovery. Patients presenting with GFR <15 mL/min or requiring dialysis at presentation have a significantly lower chance of renal recovery.
    • Histological Findings on Biopsy:
      • Percentage of cellular crescents: Higher proportion of cellular (active) crescents (vs. fibrous/sclerotic crescents) indicates more active inflammation and better potential for response to immunosuppression.
      • Degree of interstitial fibrosis and tubular atrophy (IFTA): Extensive chronic changes predict poor renal recovery.
    • Presence of Oligo-anuria: Predicts poor renal outcome.
    • Age: Older age is associated with poorer renal prognosis and higher mortality (due to increased comorbidities and treatment side effects).
    • Systemic Manifestations: Presence of diffuse alveolar hemorrhage (pulmonary-renal syndrome) indicates severe disease and poorer overall prognosis.
    • Response to Treatment: Early and sustained remission indicates better long-term outcome.
  • Survival:
    • Overall patient survival has improved significantly with modern immunosuppressive therapies.
    • 5-year patient survival rates vary by etiology: >80% for ANCA-associated vasculitis, around 60-70% for anti-GBM disease (often due to early mortality from pulmonary hemorrhage), and variable for immune complex diseases depending on the underlying condition.
    • Renal survival (avoidance of ESRD) is generally lower than patient survival. For patients on dialysis at presentation, only 10-20% may recover independent renal function.
  • Quality of Life: Can be significantly impacted by chronic kidney disease, side effects of immunosuppressive medications, recurrent infections, and chronic fatigue. Patients often require lifelong follow-up and management of comorbidities.

Prevention

  • Primary: RPGN is largely an autoimmune or severe inflammatory process, making primary prevention difficult. There are no specific vaccines or lifestyle interventions known to prevent its onset.
  • Secondary:
    • Early Diagnosis: Crucial to prevent irreversible kidney damage. High index of suspicion for anyone presenting with rapid decline in renal function, hematuria, and proteinuria, especially with systemic symptoms.
    • Prompt Initiation of Treatment: Immediate immunosuppression once RPGN is suspected or diagnosed is critical for preserving kidney function and reducing mortality. "Time is kidney."
    • Monitoring at-risk individuals: For patients with known autoimmune diseases (e.g., SLE) or risk factors (e.g., drug exposure causing ANCA), regular monitoring of urine and renal function may allow for earlier detection of renal involvement.
  • Tertiary:
    • Preventing Complications of CKD and ESRD: Aggressive management of blood pressure, dyslipidemia, anemia, and bone mineral disorders.
    • Preventing Immunosuppression-Related Complications: Prophylactic antibiotics (e.g., PJP), careful monitoring for infections, appropriate vaccinations, bone protection, and cancer screening.
    • Relapse Prevention: Adherence to maintenance immunosuppressive therapy is critical to prevent disease flares and progressive kidney damage.

Special Populations

  • Pediatric:
    • RPGN is less common in children, with post-infectious GN and IgA vasculitis (Henoch-Schönlein Purpura) being more prevalent causes than in adults.
    • Treatment principles are similar, but careful attention to growth and development, specific weight-based dosing, and long-term side effects of immunosuppression (e.g., gonadal toxicity with cyclophosphamide) are crucial. Rituximab may be preferred in some cases to reduce cyclophosphamide exposure.
  • Geriatric:
    • More common in older adults, especially ANCA-associated vasculitis.
    • Often present with atypical symptoms, higher comorbidity burden, and increased susceptibility to infections and other adverse effects of immunosuppression.
    • Dose adjustments for cyclophosphamide and other immunosuppressants may be necessary due to reduced renal function, hepatic metabolism, and bone marrow reserve. Lower initial doses and slower tapering of steroids may be considered.
    • Careful risk-benefit assessment for aggressive induction therapies.
  • Pregnancy:
    • RPGN during pregnancy is rare and poses significant challenges.
    • Management requires careful consideration of drug teratogenicity. Cyclophosphamide is generally contraindicated due to severe teratogenicity. MMF is also contraindicated.
    • Corticosteroids are generally considered safe, though may increase risk of gestational diabetes and preeclampsia. Azathioprine and rituximab are generally preferred if immunosuppression is necessary, but decisions must be individualized.
    • Close monitoring of maternal and fetal well-being is paramount. Multidisciplinary approach with nephrology, maternal-fetal medicine, and rheumatology is essential.
  • Comorbidities:
    • Diabetes Mellitus: Requires tight glycemic control to prevent worsening renal damage and reduce infection risk. Corticosteroids can exacerbate hyperglycemia.
    • Cardiovascular Disease: Aggressive management of hypertension, dyslipidemia, and volume status is vital.
    • Infections: Active infection should be aggressively treated before or concurrently with immunosuppression. Prophylaxis for opportunistic infections is essential.
    • Malignancy: History of malignancy may influence choice of immunosuppressants (e.g., cyclophosphamide has a cumulative risk of malignancy).

Clinical Pearls

  • Diagnostic:
    • Think RPGN: Any patient presenting with rapid decline in kidney function and active urine sediment (hematuria, proteinuria, RBC casts) should be considered for RPGN until proven otherwise. It's a true renal emergency.
    • Urgency of Biopsy: Kidney biopsy is not a delayed test; it is central to diagnosis and guiding specific treatment. Aim to perform it within 24-48 hours of high suspicion.
    • Serology is Key: Order ANCA (PR3, MPO), Anti-GBM, ANA, and complement levels immediately alongside routine renal labs and urinalysis. This panel helps narrow the differential before biopsy.
    • RBC casts are Gold: While not always present, their finding on urinalysis points strongly to glomerular disease and mandates urgent investigation.
  • Treatment:
    • Time is Kidney: Delay in treatment can lead to irreversible kidney damage. Start high-dose corticosteroids empirically as soon as RPGN is highly suspected, even before definitive biopsy results, especially if the patient is severely ill or has pulmonary hemorrhage.
    • Etiology-Specific Treatment: Tailor immunosuppression based on the underlying type of RPGN (ANCA vs. Anti-GBM vs. Immune Complex).
    • Plasma Exchange Indications: Crucial for Anti-GBM disease and for severe ANCA-associated vasculitis (creatinine >5.7 mg/dL or pulmonary hemorrhage).
    • Infection Prophylaxis: Do not forget PJP prophylaxis for patients on high-dose steroids or cyclophosphamide.
  • Pitfalls:
    • Delay in Diagnosis: Mistaking RPGN for other causes of AKI (e.g., pre-renal, acute tubular necrosis) can lead to critical delays.
    • Insufficient Immunosuppression: Under-dosing or premature withdrawal of immunosuppressants can lead to treatment failure or relapse.
    • Over-Immunosuppression: Leading to severe infections, bone marrow suppression, and other drug toxicities. Careful monitoring of CBC, LFTs, and clinical signs of infection is vital.
    • Ignoring Systemic Manifestations: Failure to recognize and manage extra-renal involvement (e.g., pulmonary hemorrhage, vasculitic skin lesions, neurological complications) can be fatal.
    • Inadequate Follow-up: Long-term adherence to maintenance therapy and regular monitoring are crucial for preventing relapses and managing complications.

Recent Updates

  • Guidelines:
    • KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for Glomerular Diseases (currently undergoing revision, but existing guidelines provide strong recommendations).
    • EULAR/ERA-EDTA (European League Against Rheumatism/European Renal Association – European Dialysis and Transplant Association) recommendations for the management of ANCA-associated vasculitis (updated periodically, e.g., 2022 update).
    • ACR (American College of Rheumatology) guidelines for vasculitis and lupus nephritis.
  • Evidence:
    • Rituximab in ANCA Vasculitis: Growing evidence supports rituximab as a primary induction agent, with non-inferiority to cyclophosphamide and potential superiority in preventing relapses in some contexts. It is also increasingly used for maintenance therapy.
    • Role of Plasma Exchange: Clarified role in ANCA-associated vasculitis, largely restricted to severe cases (creatinine >5.7 mg/dL or diffuse alveolar hemorrhage) following the PEXIVAS trial. Still standard for anti-GBM disease.
    • Complement Inhibition: Emerging therapies targeting the complement pathway (e.g., eculizumab, ravulizumab) are gaining traction for atypical hemolytic uremic syndrome (aHUS) and some severe complement-mediated glomerulonephritides, with ongoing research in specific RPGN subtypes.
    • Long-term Maintenance Strategies: Ongoing research focuses on optimal duration and agents for maintenance immunosuppression to balance relapse prevention with cumulative toxicity.
  • Controversies:
    • Optimal Duration of Maintenance Therapy: The ideal duration for maintenance immunosuppression in ANCA-associated vasculitis and lupus nephritis remains debated, balancing relapse risk with cumulative toxicity.
    • Role of Biologics in Immune Complex RPGN: Expanding use of biologics beyond rituximab (e.g., belimumab for SLE) and the potential for newer agents in refractory cases.
    • Management of Dialysis-Dependent RPGN: Whether to continue aggressive immunosuppression in patients already on dialysis at presentation, especially if chronic changes dominate on biopsy, is a point of debate due to low chances of renal recovery and high risk of side effects.

Key References

  • Guidelines:
    • KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International (forthcoming or recent publication).
    • Stone, J. H., et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis & Rheumatology, 73(8), e1342-e1363.
    • Fanouriakis, A., et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases, 82(1), 1-13.
  • Studies:
    • Walsh, M., et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. New England Journal of Medicine, 2020; 382(7), 622-631. (PEXIVAS trial)
    • Jones, R. B., et al. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine, 2010; 363(3), 211-220. (RAVE trial)
    • Jayne, D. R. W., et al. Randomized Trial of Rituximab versus Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis. Journal of the American Society of Nephrology, 2013; 24(7), 1163-1170. (RITUXVAS trial)
  • Reviews:
    • Jennette, J. C., & Falk, R. J. The Pathology of ANCA-Associated Vasculitis. Nature Reviews Nephrology, 2014; 10(7), 373-382.
    • Moroni, G., & Ponticelli, C. Rapidly Progressive Glomerulonephritis: A Review for Clinicians. Journal of Nephrology, 2020; 33(3), 425-442.
    • Salama, A. D., et al. Anti-glomerular basement membrane disease. Nature Reviews Disease Primers, 2017; 3(1), 17030.

Dr. Vivek's AI | For Educational Purposes Only